During the last three months, 20 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Analysts have set 12-month price targets for Biogen, revealing an average target of $281.45, a high estimate of $317.00, and a low estimate of $190.00. This current average represents a 2.31% decrease from the previous average price target of $288.11. Understanding Analyst Ratings: A Comprehensive Brea…